This study is looking at how different ways to close a patent ductus arteriosus (PDA) — a common heart problem in premature babies — affect blood flow to the brain and other organs. Researchers will compare babies who have their PDA closed with a procedure called transcatheter PDA occlusion to those who receive medicine like Tylenol. They will use a special monitor called NIRS (Near-Infrared Spectroscopy) to measure oxygen levels in the brain and kidneys before, during, and after treatment. The goal is to see if either treatment causes significant changes in these oxygen levels. We expect that both medical treatment and transcatheter occlusion will have minimal effects on these oxygen levels. This study is for infants aged 0 to 3 months in the Norton Children's NICU who need PDA closure. Currently, the status of this study is unclear.

Study design

This is an observational study involving 20 infants. It compares two groups of infants receiving different PDA treatments.

What's involved

Your infant will have NIRS monitors placed on their head and abdomen up to 24 hours before treatment. These monitors will stay on during treatment and for 5 days afterward.

Compensation

Not stated in the trial record.

Follow-up

Your infant will be monitored for 5 days after their PDA treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.